Skip to main content

Table 6 SF-36 scores (higher scores indicate less impairment).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

   Baseline SAMe Celecoxib  
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Physical Function 53 52.5 (20.8) 62.4* (22.8) 63.7* (25.1) -0.10
Role Physical 53 56.6 (37.4) 66.5* (33.6) 67.9* (38.1) -0.04
Role Emotional 53 86.8 (29.5) 88.7 (24.4) 87.4 (27.1) 0.06
Vitality 53 58.9 (14.4) 60.4 (14.0) 62.9* (14.5) -0.23
Mental Health 53 71.8 (11.4) 73.7 (11.3) 74.0 (11.8) -0.03
Social Function 53 82.3 (20.1) 84.2 (19.8) 86.3 (18.7) -0.09
Bodily Pain 53 46.8 (14.1) 59.3* (19.8) 63.1* (19.6) -0.16
General Health 53 74.6 (15.2) 75.4 (17.2) 76.6 (16.8) -0.10
General Physical 53 38.1 (8.2) 42.3* (9.5) 43.4* (10.6) -0.16
General Mental 53 54.6 (7.8) 54.1 (7.4) 54.2 (6.8) -0.02
  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib.